Seattle

1991

New York University Stern School of Business (MBA) <br/>University of Pennsylvania (BA, Molecular Biology)

Nader joined Frazier Healthcare Partners in 1991 and has served on the firm’s Management Committee, Investment Committee, and led its Growth Buyout practice since 1995. Under his leadership, the Growth Buyout team has scaled from an initial team of four to over sixty and raised over $5 billion AUM from institutional limited partners globally. <br/> <br/>During his over three-decade tenure with the firm, he has been responsible for and served on the Boards of numerous successful investments including Aspen Education Group, CHG Healthcare, Priority Solutions International, Bravo Health, Laboratory Supply Company, Pentec Health, Solis Mammography, DSI Renal, Northfield Medical, and United Digestive. He currently serves on the Boards of Elevate Patient Financial Solutions, Accuity Delivery Systems, and Effective School Solutions. <br/> <br/>Nader is a member of YPO and received his MBA from the Leonard N. Stern School of Business at New York University and a BA in Molecular Biology from the University of Pennsylvania. <br/>

Seattle

2006

Dartmouth Tuck School of Business (MBA) <br/>University of Notre Dame (BBA, Finance & Computer Applications)

Ben joined Frazier Healthcare Partners in 2006. He represents Frazier on the Boards of AirLife, CSafe, Matrix Medical Network, RevSpring, Vatica Health, and United Derm Partners. Additionally, Ben has been responsible for Frazier’s successful investments in Ascension Orthopedics, CPS Solutions, DSI Renal, Golden State Medical Supply, Laboratory Supply Company, Northfield Medical, and Parata Systems. <br/> <br/>Prior to Frazier, Ben was at Morgan Stanley Capital Partners (MSCP), focusing on investing in the healthcare sector. Before joining MSCP, he was at Morgan Stanley in the Investment Banking Division, covering the healthcare industry. Earlier, he spent time at Arthur Andersen. <br/> <br/>Ben received his MBA from the Tuck School of Business at Dartmouth and his BBA in Finance and Computer Applications from the University of Notre Dame.

Seattle

1999

Emory University School of Medicine (MD) <br/>University of Washington School of Public Health (MPH) <br/>University of Pennsylvania (BA

A cardiologist by training, Nathan has been with Frazier Healthcare Partners since 1999. Nathan currently serves on the Boards of Adare Pharma Services, Apollo Intelligence, Caravel Autism Health, EPTAM Precision, and HOPCo/CORE Orthopedics. Additionally, Nathan has led several exited investments, including BARRX, Zeltiq, Glaukos, PCI, Abode Healthcare, Silvergate Pharma, Powervision, CPS Solutions and HOPCo. <br/> <br/>Prior to joining Frazier, Nathan was an Associate Professor of Medicine and the Director of the Cardiovascular Outcomes Research Center (CORC) at the University of Washington. He previously served on the PRI Investment Committee of the Bill and Melinda Gates Foundation. <br/> <br/>Nathan earned an MD from Emory University School of Medicine and a Masters of Public Health (MPH) from the University of Washington.

Seattle

2003

Stanford University (BS, MS, Phi Beta Kappa)

Brian, a General Partner, joined Frazier Healthcare Partners in 2003. Brian currently serves on the Boards of Leiters and Matrix Medical Network. He has previously been involved in Frazier’s investments in Bravo Health, CHG Healthcare Services, Pentec Health, Priority Solutions, TridentUSA, Informed Medical Communications, Correct Care Solutions, HOPCo, and Elevate Patient Financial Solutions. Additionally, Brian leads the Growth Buyout team’s debt capital markets activities. <br/> <br/>Prior to joining Frazier, Brian worked at Summit Partners, a growth equity firm. While at Summit, he focused on identifying and evaluating investment opportunities in the healthcare, technology, and industrial sectors. <br/> <br/>Brian earned his BS and MS from Stanford University, where he was also a member of Phi Beta Kappa.

Seattle

2019

Carlson School of Management at the University of Minnesota (BSB, Finance & Marketing) <br/>Harvard Business School (MBA)

Christina joined Frazier Healthcare Partners in October 2019 as a Principal on the Growth Buyout team. In January 2022, she was promoted to Partner. Christina represents Frazier on the Boards of United Derm Partners, Accuity Delivery Systems, Apollo Intelligence, and RevSpring. <br/> <br/>Prior to Frazier, Christina was a Principal at Norwest Equity Partners, where she worked for over 10 years. In her role as a senior member of the investment team, she was involved with all aspects of the investment process, including sourcing investment opportunities across a broad array of industries, performing due diligence, structuring transactions, and serving on the Board of several portfolio companies. <br/> <br/>Before joining NEP in 2009, Christina worked as an Investment Banking Associate at Craig-Hallum Capital Group, where she executed over 20 transactions during her 30-month tenure. Before Craig-Hallum, Christina worked for LaSalle Bank as a Senior Credit Analyst, where she developed and maintained lending relationships with senior management of middle-market companies throughout Minnesota, North Dakota, and South Dakota. <br/> <br/>Christina is active in her community with several professional organizations, as well as speaking on panels and as a guest lecturer at the University of Minnesota and Harvard University. <br/> <br/>Christina holds a BSB in Finance and Marketing from the University of Minnesota and an MBA from Harvard Business School.

Seattle

2012

Wharton School of the University of Pennsylvania (BS, Economics, magna cum laude)

Phil joined Frazier Healthcare Partners in 2012, and is a Partner on the Growth Buyout investment team. He currently serves on the Boards of AirLife and CSafe. Previously, Phil served on the Board of CPS Solutions and was involved with several of Frazier’s portfolio companies, including Northfield Medical, HOPCo, Golden State Medical Supply, Solis Mammography, and DSI Renal. <br/> <br/>Prior to Frazier, Phil was an Analyst with RBC Capital Markets, where he worked on a variety of engagements, including mergers and acquisitions and leveraged finance. <br/> <br/>Phil holds a BS in Economics, magna cum laude, from the Wharton School of the University of Pennsylvania.

Seattle

2016

Kellogg School of Management at Northwestern University (MBA) <br/>Northwestern University (BS, Biomedical Engineering, Beta Theta Pi)

Kent joined Frazier Healthcare Partners in 2016 and is a Partner on the Growth Buyout investment team. Kent has been instrumental in multiple exited investments, including Parata Systems and Abode Healthcare. Additionally, Kent currently serves on the Boards of Caravel Autism Health, Effective School Solutions, and Matrix Medical Network. <br/> <br/>Before coming to Frazier, Kent spent four years with The Edgewater Funds, where he focused on leveraged buyout and growth equity investments in the healthcare, industrial, and business services industries. <br/> <br/>Prior to joining Edgewater, Kent was an Associate with CIVC Partners, a middle-market private equity firm focused on the business services and financial services industries. Previously, he worked for Dresner Partners, a middle-market investment banking firm in Chicago, and for Lehman Brothers in the investment banking division in New York. <br/> <br/>Kent holds a BS in Biomedical Engineering from Northwestern University and an MBA from The Kellogg School of Management at Northwestern University. <br/>

Seattle

2016

Marriott School of Management at Brigham Young University (BS, magna cum laude)

Ryan joined Frazier Healthcare Partners in 2016 and is a Partner on the Growth Buyout Investment team. He serves on the Boards of Elevate Patient Financial Solutions, EPTAM Precision, and Vatica Health. He has also been involved with several other Frazier portfolio companies, including PCI, United Digestive, Alteon Health, and Solis Mammography. <br/> <br/>Before joining Frazier, Ryan spent five years with Kohlberg & Company in New York, where he focused on leveraged buyout and growth equity investments. At Kohlberg, he was responsible for the origination, evaluation, and management of investments across a variety of sectors, including healthcare, business services, and financial services. <br/> <br/>Previously, Ryan worked for JPMorgan Chase & Co. in the investment banking division in New York, where he focused on mergers and acquisitions and capital offerings for financial institution clients. He was also a member of the investment team for the Troubled Asset Relief Program (TARP) of the U.S. Department of the Treasury in Washington, DC. <br/> <br/>Ryan serves on the Executive Leadership Team of the Alzheimer’s Association’s Walk to End Alzheimer’s. <br/> <br/>Ryan earned his BS from Brigham Young University, Marriott School of Management, magna cum laude.

Seattle

2016

University of North Carolina at Chapel Hill (BS, Business Administration)

Shyamal joined Frazier Healthcare Partners in 2016. He serves on the Board of Vatica Health and is involved with CSafe. In addition, Shyamal was also instrumental in multiple exited investments, including CPS Solutions, HOPCo, Parata Systems, and United Digestive. <br/> <br/>Prior to joining Frazier, Shyamal was an Analyst in the healthcare investment banking group at Harris Williams & Co. in San Francisco, where he worked with middle-market companies on a variety of corporate finance and mergers and acquisitions engagements. <br/> <br/>Shyamal received his BS in Business Administration from the University of North Carolina at Chapel Hill.

Seattle

2019

Middlebury College (BA, Economics & Environmental Economics) <br/>

Jeremy joined Frazier Healthcare Partners in 2016. He sits on the Board of Apollo Intelligence and is involved with several of Frazier’s portfolio companies, including Adare Pharma Solutions, Accuity Delivery Systems, and Leiters. Additionally, Jeremy was involved with previous Frazier portfolio company PCI Pharma Services. <br/> <br/>Before joining Frazier as an Associate in 2016, Jeremy was an Analyst in the investment banking group at Robert W Baird in Chicago. In 2018 he joined Frazier portfolio company Leiters, a manufacturer of compounded sterile pharmaceuticals, as their Director of Strategic Initiatives before re-joining the investment team in 2019 as a Senior Associate. <br/> <br/>Jeremy received his BA in Economics with a focus on Environmental Economics from Middlebury College. <br/> 

Seattle

2019

University of California, Berkeley (MBA & Masters in Public Health) <br/>FAAP – Fundacao Armando Alvares Penteado (BA, summa cum laude)

Clarissa joined Frazier Healthcare Partners in 2019. She serves on the Board of RevSpring and is involved with several of Frazier’s portfolio companies, including AirLife, EPTAM Precision, and Effective School Solutions. She has also previously been involved with Elevate Patient Financial Solutions and Alteon Health, amongst other portfolio companies. <br/> <br/>Prior to Frazier, she worked at McKinsey and Company, focused on the corporate finance and strategy practice in the technology sector, and spent three years with Bauscher Brasil, a start-up she co-founded. <br/> <br/>Before founding Bauscher, Clarissa was a Vice President at Credit Suisse, focused on healthcare and educational services industries. Previously, she worked for Morgan Stanley in Sao Paulo. In recent years, Clarissa also had a brief passage working at Goldman Sachs and Francisco Partners. <br/> <br/>Clarissa currently serves on the HCPEA Young Leaders Council. <br/> <br/>Clarissa received her BA from FAAP and her MBA and Master’s in Public Health from the University of California, Berkeley.

Seattle

2021

Indiana University (BA, Economics) <br/>

Matt joined Frazier Healthcare Partners in August 2021. He is involved with several of Frazier’s portfolio companies, including Apollo Intelligence, Elevate Patient Financial Solutions, Matrix Medical Network, and United Derm Partners. <br/> <br/>Prior to joining Frazier, Matt was an Associate at Sheridan Capital Partners, a lower middle-market private equity firm, where he focused on evaluating leveraged buyout investments in the healthcare industry. Prior to Sheridan, he was an Investment Banking Analyst at William Blair & Company, where he focused on mergers and acquisitions of middle-market healthcare companies. <br/> <br/>Matt received his BA in Economics from Indiana University. <br/>

Seattle

2022

The Wharton School (MBA) <br/>University of Notre Dame (BBA, Finance & English)

Jack joined Frazier Healthcare Partners in July 2022 as a Senior Associate on the Growth Buyout team. In January 2024, he was promoted to Vice President. He is involved with several of Frazier’s portfolio companies, including Adare Pharma Solutions, AirLife and RevSpring. <br/> <br/>Prior to joining Frazier, Jack was a Senior Associate in the Private Equities Department at the Abu Dhabi Investment Authority (ADIA), where he focused on direct investments in the Americas. Before ADIA, he was an Investment Banking Analyst at William Blair, where he focused on mergers and acquisitions of middle-market healthcare companies. <br/> <br/>Jack received his MBA from the Wharton School and his BBA in Finance and English from the University of Notre Dame.

Seattle

2019

Vanderbilt University (BA, Economics & History) <br/>

Michael joined Frazier Healthcare Partners in July 2019 on the Growth Buyout team. He is involved with several of Frazier’s portfolio companies, including Accuity Delivery Systems, Caravel Autism Health, Effective School Solutions. In addition, Michael was also instrumental in multiple exited investments, including Parata Systems, and United Digestive. <br/> <br/>Prior to joining Frazier, Michael was an Investment Banking Analyst in the healthcare investment banking group at Raymond James in Nashville, where he worked on mergers and acquisition transactions in the middle-market. <br/> <br/>Michael received his BA in Economics and History from Vanderbilt University.

Seattle

2023

Wharton School of the University of Pennsylvania (MBA) <br/>Yale University (BA, Economics)

Andrew joined Frazier Healthcare Partners in July 2023 as a Senior Associate on the Growth Buyout team. He is involved with several of Frazier's portfolio companies, including RevSpring and United Derm Partners. <br/> <br/>Prior to joining Frazier, Andrew was a Senior Manager at Zymergen, a publicly traded biotechnology company that has since been acquired by Ginkgo Bioworks. At Zymergen, Andrew worked across a variety of functions, including mergers and acquisitions, business development, and early-stage product development. <br/> <br/>Prior to Zymergen, Andrew was an Investment Banking Associate Director at UBS, where he focused on mergers and acquisitions and capital markets activities for large-cap healthcare companies. <br/> <br/>Andrew received his MBA from the Wharton School of the University of Pennsylvania and his BA in Economics from Yale University.

Seattle

2022

New York University (BS, Business) <br/>

Jennifer joined Frazier Healthcare Partners in October 2022 as an Associate on the Growth Buyout team. In January 2024, she was promoted to Senior Associate. Additionally, Jennifer has been involved with Frazier’s portfolio companies AirLife and Elevate Patient Financial Solutions. <br/> <br/>Prior to joining Frazier, Jennifer worked as an Associate at Carlyle, focused on buyout and growth investments in the healthcare sector. Before Carlyle, she was an Investment Banking Analyst at J.P. Morgan in New York, advising healthcare companies on mergers and acquisitions and capital market transactions. <br/> <br/>Jennifer received her BS in Business from New York University.

Seattle

2022

The University of Edinburgh (MA, Economics & Finance) <br/>Yale School of Management (MBA)

Volodymyr “Volo” joined Frazier Healthcare Partners in July 2022 as an Associate on the Growth Buyout team. In July 2024, Volodymyr was promoted to a Senior Associate. He is involved with several of Frazier’s portfolio companies, including Caravel Autism Health and Matrix Medical Network. <br/> <br/>Prior to joining Frazier, Volodymyr served as the COO of Hawaii Behavioral Health, a behavioral health company focused on autism and mental health services. Previously, he held Associate positions at Moelis & Company in New York and at BNP Paribas in London, where he worked on a variety of corporate finance and mergers and acquisitions engagements. <br/> <br/>Volodymyr holds an MA in Economics and Finance from the University of Edinburgh and an MBA from Yale School of Management.

Seattle

2022

Northwestern University (BA, Economics, cum laude)

Eric joined Frazier Healthcare Partners in July 2022 as an Associate on the Growth Buyout team. In July 2024, Eric was promoted to a Senior Associate. <br/> <br/>Prior to joining Frazier, Eric was an Investment Banking Analyst in the healthcare group at William Blair & Company in Chicago, IL, where he focused on mergers and acquisitions. <br/> <br/>Eric received his BA in Economics from Northwestern University.

Seattle

2024

University of Michigan (BBA, Business Administration)

Ilene joined Frazier Healthcare Partners in October 2024 as a Senior Associate on the Growth Buyout team. <br/> <br/>Prior to joining Frazier, Ilene was a Senior Associate at Grant Avenue Capital, a lower middle-market private equity firm in New York City, where she focused on buyout and growth investments in the healthcare sector. <br/> <br/>Before Grant Avenue Capital, Ilene was an Investment Banking Associate at Piper Sandler in San Francisco, advising healthcare companies on mergers and acquisitions and capital market transactions. Earlier in her career, Ilene worked at Deutsche Bank’s Capital Markets group. <br/> <br/>Ilene received her BBA in Business Administration from the University of Michigan.

Seattle

2023

Northwestern University (BA, Economics) <br/>

Daniel joined Frazier Healthcare Partners in August 2023 as an Associate on the Growth Buyout Team. <br/> <br/>Prior to joining Frazier, Daniel was an Investment Banking Analyst at Deutsche Bank in New York, advising technology, media, and telecom companies on mergers and acquisitions and capital markets transactions. <br/> <br/>Daniel received his BA in Economics at Northwestern University. <br/>

Seattle

2023

Claremont McKenna College (BA, Economics, Cum Laude)

Luke joined Frazier Healthcare Partners in July 2023 as an Associate on the Growth Buyout team. <br/> <br/>Prior to joining Frazier, Luke was an Investment Banking Analyst in the mergers and acquisitions group at TD Cowen in New York, where he focused on both public and private M&A advisory. <br/> <br/>Luke received his BA in Economics from Claremont McKenna College.

Seattle

2024

University of North Carolina at Chapel Hill (BS, Business Administration & BA, Economics)

Charles joined Frazier Healthcare Partners in July 2024 as an Associate on the Growth Buyout team. <br/> <br/>Prior to joining Frazier, Charles worked as an investment banking analyst in the Life Sciences and Healthcare group at Deloitte Corporate Finance in Charlotte, where he focused on mergers and acquisitions. <br/> <br/>Charles received his BS in Business Administration and BA in Economics from the University of North Carolina at Chapel Hill. <br/>

Seattle

2024

University of British Columbia (BCom)

Alex joined Frazier Healthcare Partners in August 2024 as an Associate on the Growth Buyout team. <br/> <br/>Prior to joining Frazier, Alex was an Analyst at TD in Vancouver, BC, where he focused on strategic and M&A advisory. <br/> <br/>Alex received his Bachelor of Commerce from the University of British Columbia. <br/>

Seattle

2024

University of Bristol (BA, Classics)

James joined Frazier Healthcare Partners in July 2024 as an Associate on the Growth Buyout Team. <br/> <br/>Prior to joining Frazier, James was an investment banker in the Mergers & Acquisitions group at Solomon Partners in New York, where he focused on both public and private M&A advisory. James also spent time on the investment banking team at Fenchurch Advisory Partners in London. <br/> <br/>James received his BA in Classics from the University of Bristol.